A RANDOMISED TRIAL OF DENTRIC CELL VACCINATION WITH NY-ESO-1 AND ALPHA- GALACTOSYLCERAMIDE IN PATIENTS WITH METASTATIC MELANOMA (ACTRN12612001101875)

被引：0

作者：

Dasyam, N. ^{[1
]}

Sharples, K. ^{[2
]}

Barrow, C. ^{[3
]}

Bauer, E. ^{[1
]}

Mester, B. ^{[1
]}

McCusker, M. ^{[4
]}

Painter, G. ^{[5
]}

Weinkove, R. ^{[3
]}

Brimble, M. ^{[6
]}

Dunbar, R. ^{[6
]}

Gasser, O. ^{[1
]}

Hermans, I. ^{[1
]}

机构：

[1] Malaghan Inst Med Res, Wellington, New Zealand

[2] Univ Otago, Dunedin Sch Med, Dunedin, New Zealand

[3] Wellington Reg Hosp, Capital Coast Dist Hlth Board, Wellington, New Zealand

[4] Univ Auckland, Canc Trials New Zealand, Auckland, New Zealand

[5] Victoria Univ Wellington, Ferrier Res Inst, Wellington, New Zealand

[6] Maurice Wilkins Ctr Mol Biodiscovery, Auckland, New Zealand

来源：

CYTOTHERAPY | 2021年 / 23卷 / 05期

关键词：

Vaccine;

D O I：

暂无

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

427

引用

页码：S98 / S98

页数：1

共 44 条

[1] A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma
Nathaniel Dasyam
Katrina J. Sharples
Catherine Barrow
Ying Huang
Evelyn Bauer
Brigitta Mester
Catherine E. Wood
Astrid Authier-Hall
Marina Dzhelali
Tess Ostapowicz
Rajiv Kumar
Jessica Lowe
Alice Maxwell
Olivia K. Burn
Geoffrey M. Williams
Sarah E. Carley
Graham Caygill
Jeremy Jones
Susanna T. S. Chan
Victoria A. Hinder
Jerome Macapagal
Monica McCusker
Robert Weinkove
Margaret A. Brimble
Gavin F. Painter
Michael P. Findlay
P. Rod Dunbar
Olivier Gasser
Ian F. Hermans
Cancer Immunology, Immunotherapy, 2023, 72 : 2267 - 2282
[2] A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma
Dasyam, Nathaniel
Sharples, Katrina J.
Barrow, Catherine
Huang, Ying
Bauer, Evelyn
Mester, Brigitta
Wood, Catherine E.
Authier-Hall, Astrid
Dzhelali, Marina
Ostapowicz, Tess
Kumar, Rajiv
Lowe, Jessica
Maxwell, Alice
Burn, Olivia K.
Williams, Geoffrey M.
Carley, Sarah E.
Caygill, Graham
Jones, Jeremy
Chan, Susanna T. S.
Hinder, Victoria A.
Macapagal, Jerome
McCusker, Monica
Weinkove, Robert
Brimble, Margaret A.
Painter, Gavin F.
Findlay, Michael P.
Dunbar, P. Rod
Gasser, Olivier
Hermans, Ian F.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (07) : 2267 - 2282
[3] Phase II trial of vaccination with full length NY-ESO-1/IMX in patients with advanced malignant melanoma.
Nicholaou, T.
Davis, I. D.
Marakovsky, E.
Miloradovic, L.
Hopkins, W.
Chen, W.
McArthur, G.
Pan, L.
Hoffman, E. W.
Old, L. J.
Cebon, J.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 117S - 117S
[4] Phase II trial of ipilimumab in patients with advanced melanoma and spontaneous preexisting immune response to NY-ESO-1 (CTLA-4 NY-ESO-1).
Haag, Georg Martin
Hassel, Jessica Cecile
Zoernig, Inka
Halama, Niels
Beckhove, Philipp
Karapanagiotou-Schenkel, Irini
Enk, Alexander
Jaeger, Dirk
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[5] A phase 1 study of NY-ESO-1 vaccine + ipilimumab (ipi) in patients with unresectable or metastatic melanoma
Slingluff, Craig
Zarour, Hassane
Postow, Michael
Friedlander, Philip
Devoe, Craig
Mauldin, Ileana
Smith, Kelly
Macri, Mary
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[6] Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma
Sabado, Rachel Lubong
Pavlick, Anna
Gnjatic, Sacha
Cruz, Crystal M.
Vengco, Isabelita
Hasan, Farah
Spadaccia, Meredith
Darvishian, Farbod
Chiriboga, Luis
Holman, Rose Marie
Escalon, Juliet
Muren, Caroline
Escano, Crystal
Yepes, Ethel
Sharpe, Dunbar
Vasilakos, John P.
Rolnitzsky, Linda
Goldberg, Judith D.
Mandeli, John
Adams, Sylvia
Jungbluth, Achim
Pan, Linda
Venhaus, Ralph
Ott, Patrick A.
Bhardwaj, Nina
CANCER IMMUNOLOGY RESEARCH, 2015, 3 (03) : 278 - 287
[7] Evaluation of cyclophosphamide as an immune enhancer for the NY-ESO-1/ISCOMATRIX vaccine in patients with metastatic melanoma.
Klein, Oliver
Davis, Ian D.
McArthur, Grant A.
Haydon, Andrew Mark
Parente, Phillip
Dimopoulos, Nektaria
Jackson, Heather
Maraskovsky, Eugene
Hopkins, Wendie
Stan, Rodica
Chen, Weisan
Cebon, Jonathan S.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[8] A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients
Gasser, Olivier
Sharples, Katrina J.
Barrow, Catherine
Williams, Geoffrey M.
Bauer, Evelyn
Wood, Catherine E.
Mester, Brigitta
Dzhelali, Marina
Caygill, Graham
Jones, Jeremy
Hayman, Colin M.
Hinder, Victoria A.
Macapagal, Jerome
McCusker, Monica
Weinkove, Robert
Painter, Gavin F.
Brimble, Margaret A.
Findlay, Michael P.
Dunbar, P. Rod
Hermans, Ian F.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (02) : 285 - 298
[9] Phase 1 study of NY-ESO-1 vaccine + ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Slingluff, Craig L.
Zarour, Hassane M.
Postow, Michael A.
Friedlander, Philip Adam
Devoe, Craig E.
Smith, Kelly
Deacon, Donna
Macri, Mary J.
Ryan, Aileen
Venhaus, Ralph Rudolph
Wolchok, Jedd D.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[10] A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients
Olivier Gasser
Katrina J. Sharples
Catherine Barrow
Geoffrey M. Williams
Evelyn Bauer
Catherine E. Wood
Brigitta Mester
Marina Dzhelali
Graham Caygill
Jeremy Jones
Colin M. Hayman
Victoria A. Hinder
Jerome Macapagal
Monica McCusker
Robert Weinkove
Gavin F. Painter
Margaret A. Brimble
Michael P. Findlay
P. Rod Dunbar
Ian F. Hermans
Cancer Immunology, Immunotherapy, 2018, 67 : 285 - 298

← 1 2 3 4 5 →